Table 3.

Relations between treatment-induced changes in symptom severity, as measured by the Liebowitz social anxiety scale (LSAS), and corresponding changes in serotonin transporter (SERT) occupancy and dopamine (DAT) transporter binding potential (BP_ND).

	x	y	z	Z	PFWE	Cluster volumea
Serotonin transporter
SSRIb + ICBTc
Positive
R NAcc	6	10	−12	3.62	0.002	272
R Caudate (NAcc)	6	12	−10	3.51	0.034	48
L Putamen	−26	−4	10	3.42	0.042	8
L ACC	−8	40	−6	3.57	0.007	8
Placebo + ICBTc
–
Dopamine transporter
SSRI + ICBTd
Negative
L Amygdala	−28	−4	−24	2.96	0.035	8
Placebo + ICBTd
Positive
L NAcc	−6	8	−8	2.97	0.015	336
SSRI + ICBT < Placebo + ICBT
L NAcc	−4	10	−6	3.55	<0.001	512
R NAcc	4	8	−8	2.71	0.018	56
L Thalamus	−14	−26	2	3.53	0.016	376

MNI Montreal Neurological Institute, L left, R right, NAcc Nucleus Accumbens, ACC Anterior Cingulate Cortex.

^aCluster volume in mm³.

^bSelective Serotonin Reuptake Inhibitor, escitalopram.

^cHigh SSRI occupancy reflects decreased BP_ND.

^dPercent change of BP_ND.